Avoid. Cornix (CRNX) scores poorly across fundamentals (Value Compounder 14/100) with execution risk concentrated in two unproven catalysts: PALSONIFY commercialization and paltusotine's Phase 3 approval for Cushing's syndrome. Leadership alignment is weak (47/100), and the company lacks meaningful financial traction or moat to justify risk exposure at this stage.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for CRNX:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 21/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates CRNX (CRNX) at 21/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Cornix (CRNX) scores poorly across fundamentals (Value Compounder 14/100) with execution risk concentrated in two unproven catalysts: PALSONIFY commercialization and paltusotine's Phase 3 approval for Cushing's syndrome. Lead
CRNX's current Stocky Verdict is 21/100, placing it in the "Avoid" band. This composite combines a 14/100 Compounder score, 47/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for CRNX yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
CRNX scores 47/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
CRNX's Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to CRNX.
Sign up free and unlock the full analysis on CRNX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for CRNX in the app.
